Ligand Pharmaceuticals Incorporated (LGND)
| Market Cap | 2.22B |
| Revenue (ttm) | 181.49M |
| Net Income (ttm) | -132.62M |
| Shares Out | 19.29M |
| EPS (ttm) | -7.11 |
| PE Ratio | n/a |
| Forward PE | 109.12 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 51,878 |
| Open | 112.00 |
| Previous Close | 112.54 |
| Day's Range | 112.00 - 115.54 |
| 52-Week Range | 77.53 - 129.90 |
| Beta | 0.71 |
| Analysts | Strong Buy |
| Price Target | 144.71 (+25.88%) |
| Earnings Date | Aug 5, 2025 |
About LGND
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neurobla... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for LGND stock is "Strong Buy." The 12-month stock price forecast is $144.71, which is an increase of 25.88% from the latest price.
News
Ligand Announces 2025 Investor Day in New York City
JUPITER, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor Day in New York City on Tuesday, December 9, 2025 at 1...
Ligand to Ring the Nasdaq Opening Bell on May 19, 2025
JUPITER, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that the company will ring The Nasdaq Stock Market Opening Bell on Monday, May 19, 20...
Ligand Pharmaceuticals Incorporated (LGND) Q1 2025 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Melanie Herman – Executive Director-Investor Relations Todd Davis – Chie...
Ligand Reports First Quarter 2025 Financial Results
First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Cr...
Ligand to Participate in May Investor Conferences
JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor c...
Ligand to Report First Quarter 2025 Financial Results on May 8, 2025
JUPITER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2025 financial results before the opening of the ...
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMI™ ZELSUVMI is an FDA-designated novel drug a...
Ligand to Participate in March Investor Conferences
JUPITER, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza w...
Ligand Pharmaceuticals Incorporated (LGND) Q4 2024 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Melanie Herman - Senior Director of Financial Planning and Analysi...
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results
Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share 1 of $6...
Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences
Capital will fund Castle Creek's D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $50 million and a syndicate of co-investors...
Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
JUPITER, Fla.--(BUSINESS WIRE)--Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025.
Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
JUPITER, Fla.--(BUSINESS WIRE)--Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.
Looking Back On Ligand Pharmaceuticals
Today, I am circling back to Ligand Pharmaceuticals for the first time since late 2023. The stock has had a nice run in recent months and management has a solid game plan to grow revenues at north of ...
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will host its Investor and Analyst Day in Boston today. The event will feature presentations from Ligand CEO Todd Dav...
Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies
I continue to rate Ligand Pharmaceuticals stock as a "Buy" citing strong liquidity and a clean balance sheet. Its Q3 2024 earnings report beat on the top and bottom lines raising prior guidance, reinf...
Ligand to Present at Stifel 2024 Healthcare Conference
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the...
Ligand Pharmaceuticals Incorporated (LGND) Q3 2024 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Melanie Herman - Senior Director of Financial Planning and Analysis...
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance.
Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor and Analyst Day in Boston on Tuesday, December 10, 2024 from 10:30 a.m....
Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2024 financial results before the opening of the U.S. financial mar...
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received full approval from the U.S. F...
CD40 Ligand Market - Global Monoclonal Antibody, Polyclonal Antibody, Autoimmune Disease Treatment, Immunotherapy, Vaccine Development Forecast 2024-2030
Dublin, Aug. 30, 2024 (GLOBE NEWSWIRE) -- The "Global CD40 Ligand Market by Type (Monoclonal Antibody, Polyclonal Antibody), Application (Autoimmune Disease Treatment, Immunotherapy, Vaccine Developme...
Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the...